Payment overview · 2025
General Payments
$1,151.51
67 reported records · 24 companies
Healthcare provider profile · identity verified
Billy Ray Price, MD
Allopathic & Osteopathic Physicians|Family Medicine · MOULTRIE, GA · NPI 1841369949
Verified facts
What the public records show
CMS Open Payments records show Billy Ray Price, MD received $1,151.51 in general payments during 2025 across 67 reported records.
GlaxoSmithKline, LLC. accounted for 12.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 45 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Linzess, Mounjaro, Ozempic, Rexulti, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 169 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $140.84 | 12.2% | 10 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $110.11 | 9.6% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $92.08 | 8.0% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $89.92 | 7.8% | 5 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $88.01 | 7.6% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $85.67 | 7.4% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $66.40 | 5.8% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $65.73 | 5.7% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $65.41 | 5.7% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $63.62 | 5.5% | 4 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $40.60 | 3.5% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $32.94 | 2.9% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $32.09 | 2.8% | 2 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $21.71 | 1.9% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $21.33 | 1.9% | 1 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $18.95 | 1.6% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $17.58 | 1.5% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $17.36 | 1.5% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.39 | 1.4% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.92 | 1.4% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.09 | 1.3% | 1 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $14.36 | 1.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.00 | 1.2% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $5.40 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,151.51 | 67 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $123.35 | 9 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $88.01 | 5 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $66.40 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $65.73 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $65.41 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $63.62 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $55.37 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $55.37 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $53.37 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $52.97 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $52.97 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $50.43 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $48.05 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $41.65 | 2 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $40.60 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $34.55 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $32.30 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $32.09 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $30.77 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $30.76 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $26.38 | 1 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $21.71 | 1 | 2025 |
Source payment records
|
|||||
| BEYFORTUS Normalized: beyfortus |
Biological | SANOFI PASTEUR INC. | $21.33 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $21.33 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE QUADRIVALENT NORTHERN HEMISPHERE Normalized: fluzone quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $21.33 | 1 | 2025 |
Source payment records
|
|||||
| MENQUADFI Normalized: menquadfi |
Biological | SANOFI PASTEUR INC. | $21.33 | 1 | 2025 |
Source payment records
|
|||||
| VAXELIS Normalized: vaxelis |
Biological | SANOFI PASTEUR INC. | $21.33 | 1 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $18.95 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $18.90 | 1 | 2025 |
Source payment records
|
|||||
| PENBRAYA Normalized: penbraya |
Biological | PFIZER INC. | $18.09 | 1 | 2025 |
Source payment records
|
|||||
| TRUMENBA Normalized: trumenba |
Biological | PFIZER INC. | $18.09 | 1 | 2025 |
Source payment records
|
|||||
| AJOVY Normalized: ajovy |
Biological | Teva Pharmaceuticals USA, Inc. | $17.58 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $17.49 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $17.49 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $17.36 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $16.46 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $16.39 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $15.92 | 1 | 2025 |
Source payment records
|
|||||
| XHANCE Normalized: xhance |
Drug | Paratek Pharmaceuticals, Inc. | $15.92 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $15.09 | 1 | 2025 |
Source payment records
|
|||||
| COLLAGENASE SANTYL Normalized: collagenase santyl |
Drug | Smith+Nephew, Inc. | $14.36 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.04 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.04 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.00 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $5.40 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 77 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 87 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 58 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 169 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 44 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
58 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
77 | 16 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
87 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
87 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
169 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
71 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 290 | 64 |
| Levothyroxine Sodium | Levothyroxine Sodium | 250 | 50 |
| Omeprazole | Omeprazole | 216 | 39 |
| Metoprolol Succinate | Metoprolol Succinate | 191 | 37 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 184 | 27 |
| Pantoprazole Sodium | Pantoprazole Sodium | 173 | 41 |
| Alprazolam | Alprazolam | 171 | 27 |
| Gabapentin | Gabapentin | 170 | 35 |
| Mounjaro | Tirzepatide | 169 | 21 |
| Amlodipine Besylate | Amlodipine Besylate | 154 | 36 |
| Atenolol | Atenolol | 153 | 31 |
| Potassium Chloride | Potassium Chloride | 149 | 34 |
| Furosemide | Furosemide | 143 | 31 |
| Metformin Hcl | Metformin Hcl | 129 | 28 |
| Losartan Potassium | Losartan Potassium | 128 | 37 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 124 | 26 |
| Pregabalin | Pregabalin | 109 | 25 |
| Allopurinol | Allopurinol | 105 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 102 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 98 | 18 |
| Tizanidine Hcl | Tizanidine Hcl | 98 | 23 |
| Nifedipine Er | Nifedipine | 96 | 27 |
| Jardiance | Empagliflozin | 87 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 85 | 12 |
| Lisinopril | Lisinopril | 81 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 80 | 25 |
| Famotidine | Famotidine | 78 | 17 |
| Farxiga | Dapagliflozin Propanediol | 77 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 72 | 15 |
| Prednisone | Prednisone | 72 | 50 |
| Duloxetine Hcl | Duloxetine Hcl | 71 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 71 | 15 |
| Trulicity | Dulaglutide | 71 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 67 | 17 |
| Topiramate | Topiramate | 67 | suppressed |
| Meloxicam | Meloxicam | 66 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 66 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 62 | 13 |
| Doxepin Hcl | Doxepin Hcl | 60 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 59 | 13 |
| Linzess | Linaclotide | 58 | 12 |
| Tramadol Hcl | Tramadol Hcl | 55 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 51 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 50 | 14 |
| Simvastatin | Simvastatin | 50 | 12 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 50 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 49 | suppressed |
| Aripiprazole | Aripiprazole | 48 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 48 | suppressed |
| Celecoxib | Celecoxib | 47 | 14 |
| Trazodone Hcl | Trazodone Hcl | 45 | suppressed |
| Ozempic | Semaglutide | 44 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 43 | 13 |
| Metformin Hcl Er | Metformin Hcl | 43 | suppressed |
| Glimepiride | Glimepiride | 42 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 41 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 40 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 40 | suppressed |
| Rybelsus | Semaglutide | 40 | suppressed |
| Spironolactone | Spironolactone | 40 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 39 | suppressed |
| Carvedilol | Carvedilol | 38 | 12 |
| Chlorthalidone | Chlorthalidone | 36 | suppressed |
| Levemir Flexpen | Insulin Detemir | 36 | 12 |
| Promethazine Hcl | Promethazine Hcl | 36 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 36 | 16 |
| Lorazepam | Lorazepam | 35 | suppressed |
| Mirtazapine | Mirtazapine | 35 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 35 | suppressed |
| Levetiracetam | Levetiracetam | 34 | suppressed |
| Xarelto | Rivaroxaban | 34 | suppressed |
| Bupropion Xl | Bupropion Hcl | 33 | suppressed |
| Naproxen | Naproxen | 33 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 32 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 32 | suppressed |
| Estradiol | Estradiol | 32 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 31 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 31 | suppressed |
| Baclofen | Baclofen | 31 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 31 | suppressed |
| Eliquis | Apixaban | 31 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 31 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 30 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 29 | suppressed |
| Nitroglycerin | Nitroglycerin | 29 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 29 | suppressed |
| Digoxin | Digoxin | 28 | suppressed |
| Methadone Hcl | Methadone Hcl | 28 | suppressed |
| Entresto | Sacubitril/Valsartan | 27 | 11 |
| Tresiba Flextouch U-200 | Insulin Degludec | 27 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 26 | 21 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 26 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 26 | suppressed |
| Novolog Flexpen | Insulin Aspart | 26 | 11 |
| Colchicine | Colchicine | 25 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 25 | suppressed |
| Memantine Hcl | Memantine Hcl | 25 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 25 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 24 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 24 | suppressed |
| Diazepam | Diazepam | 24 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 23 | suppressed |
| Clonazepam | Clonazepam | 23 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 23 | suppressed |
| Nystatin | Nystatin | 23 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Acyclovir | Acyclovir | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 17 |
| Carisoprodol | Carisoprodol | 20 | suppressed |
| Cefdinir | Cefdinir | 20 | 18 |
| Fluconazole | Fluconazole | 20 | 15 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Bumetanide | Bumetanide | 17 | suppressed |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Cephalexin | Cephalexin | 15 | 14 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Amoxicillin | Amoxicillin | 13 | 11 |
| Ezetimibe | Ezetimibe | 13 | suppressed |
| Lubiprostone | Lubiprostone | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Finasteride | Finasteride | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Rexulti | Brexpiprazole | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,151.51 · 67 records | GlaxoSmithKline, LLC. | ABRYSVO, ACCRUFER, AIRSUPRA, AJOVY, AREXVY, Auvelity, Azstarys, BEYFORTUS, CAPLYTA, COLLAGENASE SANTYL, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE QUADRIVALENT NORTHERN HEMISPHERE, GVOKE HYPOPEN, IBSRELA, JARDIANCE, KRYSTEXXA, Kerendia, LINZESS, MENQUADFI, MOUNJARO, NURTEC ODT, NUZYRA, OTEZLA, Ozempic, PENBRAYA, PREVNAR 20, QULIPTA, QUTENZA, REPATHA, REXULTI, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, TRUMENBA, UBRELVY, VAXELIS, VOQUEZNA, VRAYLAR, Wegovy, XHANCE, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error